Alcidion Group Ltd
ASX:ALC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.044
0.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alcidion Group Ltd
Alcidion Group Ltd
Common Stock
Alcidion Group Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alcidion Group Ltd
ASX:ALC
|
Common Stock
AU$115.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
41%
|
CAGR 10-Years
30%
|
|
|
4DMedical Ltd
ASX:4DX
|
Common Stock
AU$218.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Common Stock
$36.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Pro Medicus Ltd
ASX:PME
|
Common Stock
AU$23.6m
|
CAGR 3-Years
129%
|
CAGR 5-Years
65%
|
CAGR 10-Years
53%
|
|
|
Medibio Ltd
ASX:MEB
|
Common Stock
AU$101.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Medadvisor Ltd
ASX:MDR
|
Common Stock
AU$116.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Alcidion Group Ltd
Glance View
Alcidion Group Ltd. provides intelligent health informatics technology that empowers healthcare professionals with clinical decision support systems to ensure the quality of care for the patients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The company is engaged in development, licensing and reselling its healthcare software products through its strategic partners. The company also delivers product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom. The Company’s healthcare software products include Miya, Patientrack, Smartpage and ExtraMed. Miya Precision is a clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. Smartpage is a smartphone and Web-based system for hospital communication and task management provides solution to both clinical and non-clinical users. Patientrack is a solution that supports the capture of that data at the bedside, whether directly entered on a tablet or integrated from patient monitors. Its clinical solutions use digital technology.
See Also
What is Alcidion Group Ltd's Common Stock?
Common Stock
115.5m
AUD
Based on the financial report for Jun 30, 2024, Alcidion Group Ltd's Common Stock amounts to 115.5m AUD.
What is Alcidion Group Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
30%
Over the last year, the Common Stock growth was 5%. The average annual Common Stock growth rates for Alcidion Group Ltd have been 25% over the past three years , 41% over the past five years , and 30% over the past ten years .
You don't have any saved screeners yet
